spondyloarthropathy: A group of inflammatory rheumatic diseases associated with arthritis and enthesitis, and often involving the axial skeleton. The most common form of spondyloarthritis is ankylosing spondylitis. Other forms include axial spondyloarthritis, peripheral spondyloarthritis, reactive arthritis, psoriatic arthritis/spondylitis and enteropathic arthritis/spondylitis.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
82 |
4. Check minimum number of eventsNone |
82 |
5. Include endpointsNone |
82 |
6. Filter based on genotype QC (FinnGen only) |
76 |
Control definitions (FinnGen only)
- Control exclude
- M13_DORSOPATHY
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- M46
- Name in latin
- Aliae spondylopathiae infectiosae
Similar endpoints
↥List of similar endpoints to
Other infective spondylopathies
based on the number of shared cases.
Similar with more cases:
- Autoimmune diseases related-to ILD
- Spondylopathies
- Dorsopathies
- Diseases of the musculoskeletal system and connective tissue
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 542 | 218 | 318 |
| Only index persons | 472 | 194 | 278 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 62.03 | 62.76 | 61.63 |
| Only index persons | 61.15 | 61.14 | 61.16 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 76 | 36 | 40 |
| Unadjusted period prevalence (%) | 0.02 | 0.01 | 0.02 |
| Median age at first event (years) | 62.65 | 63.66 | 61.74 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 78
- Matched controls
- 780
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M46.5
ICD-10 Finland
Other infective spondylopathies
+∞
112.2
78
*
M48.0
ICD-10 Finland
Spinal stenosis
170.3
24.1
24
*
M46.4
ICD-10 Finland
Discitis, unspecified
+∞
23.0
21
*
M51.1
ICD-10 Finland
Lumbar and other intervertebral disc disorders with radiculopathy
75.2
20.2
22
*
M46.3
ICD-10 Finland
Infection of intervertebral disc (pyogenic)
+∞
19.6
18
*
N02AX02
ATC
tramadol; systemic, rectal
9.0
18.8
59
200
N03AX16
ATC
[U] pregabalin
8.2
18.5
34
67
A41.0
ICD-10 Finland
Sepsis due to Staphylococcus aureus
107.2
16.3
17
*
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
29.2
15.2
20
9
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
49.4
13.8
16
*
ABC36
NOMESCO Finland
Decompression of lumbar nerve roots
+∞
12.9
12
*
J04AB02
ATC
rifampicin; systemic
139.8
11.8
12
*
M46.9
ICD-10 Finland
Inflammatory spondylopathy, unspecified
+∞
11.7
11
*
M54.5
ICD-10 Finland
Low back pain
5.2
11.4
34
101
M51.3
ICD-10 Finland
Other specified intervertebral disc degeneration
69.9
11.0
12
*
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
6.3
10.5
21
43
J01FF01
ATC
clindamycin; systemic
4.7
10.4
39
137
A49.9
ICD-10 Finland
Bacterial infection, unspecified
5.6
10.3
24
57
R50.9
ICD-10 Finland
Fever, unspecified
5.2
9.8
26
69
NA3CG
NOMESCO Finland
Lumbar spine extensive MRI examination with high intensity magnet
+∞
9.6
9
*
J01MA12
ATC
levofloxacin; systemic
4.6
8.8
28
85
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
4.9
7.9
21
55
ABC16
NOMESCO Finland
Microsurgical excision of lumbar intervertebral disc displacement
+∞
7.4
7
*
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
22.6
7.3
10
5
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
3.6
7.3
44
205
L03
ICPC
Low back symptom/complaint
3.9
7.3
29
103
C03CA01
ATC
furosemide; systemic
3.5
7.0
43
202
J01MA02
ATC
ciprofloxacin; systemic
3.5
6.9
42
195
N02AA05
ATC
oxycodone; systemic
3.8
6.8
27
95
M45
ICD-10 Finland
Ankylosing spondylitis
75.8
6.5
7
*
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
3.4
6.4
34
144
N06AA09
ATC
amitriptyline; systemic
7.5
6.2
14
22
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
13
16
9.50
6.64
1.9
1.4
—
—
—
0
0
15
30
5.93
5.61
1.7
1.1
—
—
—
0
0
9
8
12.50
5.44
4.0
3.0
14.20
17.95
%
—
9
8
15
40
4.40
5.39
3.4
2.5
46.63
51.06
ml/min/173m2
—
8
17
44
235
3.00
5.37
5.2
3.2
—
—
—
0
0
26
103
3.29
5.32
2.8
2.0
—
—
—
0
0
10
13
8.63
5.02
2.2
1.2
—
—
—
0
0
55
353
2.89
4.46
19.5
10.9
4.70
4.13
e9/l
0.87
50
316
25
108
2.94
4.33
4.4
2.9
2.27
1.61
e6/l
0.22
17
65
35
182
2.67
4.26
4.3
3.1
0.31
0.38
e6/l
0.12
28
135
17
60
3.34
4.10
4.1
1.9
0.18
0.21
g/l
0.69
17
54
15
50
3.48
3.94
2.2
1.5
—
—
—
0
0
20
80
3.02
3.93
2.9
1.9
—
—
—
0
0
19
75
3.03
3.81
3.1
1.9
—
—
—
0
0
10
23
4.82
3.45
1.8
1.3
—
—
—
0
0
13
39
3.79
3.43
15.6
12.0
26.29
24.95
mmol/l
0.69
13
39
46
294
2.38
3.40
3.4
2.7
—
—
estimate
—
0
0
22
101
2.64
3.33
4.3
3.1
2.47
2.33
e6/l
0.03
14
59
46
297
2.34
3.29
7.5
4.0
31.76
35.21
g/l
2.93
46
278
7
12
6.28
3.09
1.3
1.2
—
—
—
0
0
10
28
3.94
2.90
1.9
2.0
—
—
—
0
0
28
157
2.22
2.69
3.0
2.4
—
—
—
0
0
8
20
4.33
2.65
1.1
1.4
—
—
—
0
0
44
297
2.10
2.62
2.0
2.1
87.24
91.66
pmol/l
0.24
22
143
20
99
2.37
2.54
3.3
1.9
18.80
24.10
%
0.93
20
93
19
92
2.41
2.53
5.3
4.9
1.15
1.07
mmol/l
0.25
19
87
45
316
2.00
2.31
3.3
2.5
—
—
—
0
0
5
9
5.85
2.24
1.4
1.3
—
—
—
0
0
5
11
4.77
1.97
1.8
1.3
—
—
—
0
0
42
299
1.88
1.97
13.8
6.5
1.19
1.21
mmol/l
0.61
42
267
11
47
2.56
1.87
21.5
11.7
93.62
93.45
%
0.04
11
47
37
258
1.83
1.81
3.9
4.2
9.45
13.02
mg/mmol
0.29
24
161
9
36
2.69
1.80
4.6
1.1
9.18
10.69
g/l
—
9
31
5
13
4.03
1.74
3.8
3.7
—
—
—
0
0
16
85
2.11
1.70
15.6
7.9
2.96
0.85
mmol/l
1.16
11
72
6
19
3.33
1.69
2.0
2.3
—
—
—
0
0
14
71
2.18
1.66
6.9
3.0
—
—
—
0
0
11
50
2.40
1.66
6.5
2.5
0.61
0.59
%
0.08
11
50
5
14
3.74
1.64
1.6
1.7
—
—
—
0
0
45
341
1.76
1.61
8.6
3.8
0.00
0.00
estimate
-0.00
11
75
0
43
0.00
1.58
0.0
2.0
—
3.60
—
0
34
21
127
1.89
1.57
5.8
3.1
0.79
0.81
mmol/l
0.33
21
122
45
343
1.74
1.56
8.6
3.8
0.00
0.00
estimate
—
10
77
45
347
1.70
1.46
9.0
3.8
0.00
0.00
estimate
—
9
66
12
61
2.14
1.42
10.0
3.6
1.20
1.23
mmol/l
1.17
12
52
5
17
3.07
1.38
1.8
1.3
—
—
—
0
0
5
18
2.89
1.30
2.0
1.8
—
—
—
0
0
10
50
2.15
1.22
23.4
11.1
0.64
0.60
%
—
10
50
10
50
2.15
1.22
23.4
11.1
1.56
1.15
%
—
10
50
17
105
1.79
1.18
20.4
7.5
103.18
104.23
mmol/l
0.39
17
105
10
51
2.10
1.17
7.2
2.5
1.13
1.04
%
—
10
51
5
21
2.47
1.10
1.2
1.6
—
—
—
0
0
5
22
2.36
1.05
1.8
1.6
—
—
—
0
0
5
22
2.36
1.05
2.4
1.7
73.60
89.09
%
—
5
22
31
237
1.51
0.94
3.5
3.5
1139.10
1581.66
ng/l
0.92
26
201
16
105
1.66
0.90
1.3
1.3
55.57
42.97
iu/ml
—
6
38
14
90
1.68
0.85
1.4
1.3
1.46
21.76
u/ml
—
8
28
5
23
2.25
0.77
1.8
1.7
—
—
—
0
0
5
24
2.15
0.76
1.6
1.2
—
—
—
0
0
7
38
1.92
0.76
4.4
1.7
—
—
—
0
0
36
294
1.42
0.75
6.8
3.7
36.08
50.42
ng/l
0.38
29
222
19
137
1.51
0.74
9.3
4.2
1.02
1.02
kg/l
1.35
12
98
61
656
0.68
0.62
6.3
6.3
2.45
2.57
mmol/l
0.52
54
591
0
20
0.00
0.61
0.0
1.5
—
0.82
—
0
14
68
633
1.58
0.61
51.0
15.1
41.46
23.08
mg/l
1.35
62
513
24
193
1.35
0.52
10.3
3.7
0.00
0.00
estimate
—
10
69
10
68
1.54
0.50
1.1
1.5
—
—
—
0
0
31
261
1.31
0.49
9.5
3.9
0.00
0.00
estimate
—
10
62
11
79
1.46
0.43
1.2
1.2
—
—
—
0
0
16
126
1.34
0.39
1.4
1.2
0.68
0.77
u/ml
—
6
31
5
39
1.30
0.23
7.2
2.7
21.82
23.54
mmol/l
—
5
39
49
461
1.17
0.22
3.5
4.2
14.92
15.15
pmol/l
0.23
43
405
0
11
0.00
0.21
0.0
1.8
—
—
—
0
0
10
83
1.23
0.16
13.0
7.0
—
—
—
0
0
68
695
0.83
0.13
62.3
23.6
91.67
91.58
fl
0.07
68
682
68
695
0.83
0.13
63.3
23.7
127.94
135.43
g/l
3.38
68
681
68
695
0.83
0.13
65.0
24.1
38.92
40.39
%
1.90
68
681
5
62
0.79
0.08
2.0
1.6
—
—
—
0
0
68
668
1.14
0.08
49.9
18.8
139.25
139.74
mmol/l
0.91
68
648
21
198
1.08
0.06
4.5
4.3
23.21
22.04
%
0.09
12
95
19
198
0.95
0.02
7.2
3.5
0.00
0.00
estimate
—
9
59
68
687
0.92
0.02
53.8
21.1
80.41
79.95
umol/l
0.04
68
672
52
516
1.02
0.00
55.6
20.2
14.60
13.74
%
3.11
52
511
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
5.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
63.30
—
0
5
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint M13_SPONDYLOINFECTION and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_SPONDYLOINFECTION | 1.757 [1.21, 2.55] | 0.003 |
| Birth year | 0.998 [0.99, 1.01] | 0.609 |
During the follow-up period (1.1.1998 — 31.12.2019), 73 out of 189 females with M13_SPONDYLOINFECTION died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_SPONDYLOINFECTION | 1.879 [1.35, 2.62] | < 0.001 |
| Birth year | 0.986 [0.98, 1.0] | 0.003 |
During the follow-up period (1.1.1998 — 31.12.2019), 102 out of 266 males with M13_SPONDYLOINFECTION died.
Mortality risk
Mortality risk for people of age
years, who have M13_SPONDYLOINFECTION.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.202% | 0.326% |
| 5 | 1.082% | 2.174% |
| 10 | 2.763% | 5.34% |
| 15 | 5.439% | 9.837% |
| 20 | 9.668% | 17.039% |
Relationships between endpoints
↥Index endpoint: M13_SPONDYLOINFECTION – Other infective spondylopathies
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data